论文部分内容阅读
骨髓中Ⅰ型与Ⅱ型原始细胞的和>5％—<20％为原始细胞过多性难治性贫血(RAEB);>20％—<30％为转化中RAEB;>30％为急粒白血病(AML)。 RAEB的经过血液学异常一般较稳定,原始细胞数持续6个月以上不增加为本症的诊断标准之一。作者归纳了1976—1983年有关RAEB的8篇报道,共30例。从诊断起,平均生存期为14.7月,范围6.2—26.5月,以1—2年居多。向AML的移行率为10—75％,平均53％。与RAEB预后相关的因素为:(1)血细胞减少的程度;(2)骨髓原始细胞比率,(3)造血干细胞的异常;(4)染色体异常;(5)红细胞~(59)Fe利用率减低;(6)血清维生素B12增加,(7)末梢血中存在原始细胞,(8)存在Auer小体等。显著异常者预后不佳,或因出血、感染死亡,或移行为AML。
> 5% - <20% of type I and type II blasts in the bone marrow are erythroblasts in RAEB;> 20% - <30% are RAEBs in conversion;> 30% Leukemia (AML). RAEB hematological abnormalities are generally more stable, the number of primitive cells for more than 6 months does not increase as one of the diagnostic criteria for the disease. The authors summarized eight articles from 1976 to 1983 on RAEB, for a total of 30 cases. From diagnosis, the average survival time was 14.7 months, ranging from 6.2 to 26.5 months, mostly in 1-2 years. The migration rate to AML is 10-75% with an average of 53%. The factors associated with the prognosis of RAEB were: (1) the extent of cytopenia; (2) the ratio of bone marrow blasts; (3) the abnormalities of hematopoietic stem cells; (4) the chromosomal abnormalities; ; (6) increase in serum vitamin B12, (7) presence of blast cells in peripheral blood, (8) presence of Auer bodies, and the like. Patients with significant abnormalities have poor prognosis, death due to bleeding, infection, or migratory AML.